KR20070039554A - 신경 재생 - Google Patents
신경 재생 Download PDFInfo
- Publication number
- KR20070039554A KR20070039554A KR1020077001652A KR20077001652A KR20070039554A KR 20070039554 A KR20070039554 A KR 20070039554A KR 1020077001652 A KR1020077001652 A KR 1020077001652A KR 20077001652 A KR20077001652 A KR 20077001652A KR 20070039554 A KR20070039554 A KR 20070039554A
- Authority
- KR
- South Korea
- Prior art keywords
- nerve
- cells
- bmp
- cell
- vector
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
번호 | 이름 | 기능 |
I | 후각신경 | 후각 |
II | 시신경 | 시력 |
III | 안구운동신경 | 눈 근육 일부와 눈꺼풀의 운동 제어 |
IV | 활차신경 | 눈 근육 일부와 운동 제어 |
V | 삼차신경 | 저작근과 안면 감각 일부 |
VI | 외전신경 | 눈 근육 일부와 운동 제어 |
VII | 안면신경 | 안면근육의 운동 제어, 타액분비, 맛과 피부감각 |
VIII | 청신경 | 균형, 정적인 감각과 청각 |
IX | 설인신경 | 타액분비, 피부의 감각, 맛과 내장 |
X | 미주신경 | 심장과 내장의 운동제어, 흉부, 인두 및 복부 내장으로부터의 감각 |
XI | 부신경 | 인두와 어깨에 대한 운동 자극 |
XII | 설하신경 | 혀, 골격 근육 일부, 내장 일부, 피부와 내장 감각의 운동 제어 |
2 주 | 4 주 | 6 주 | 8 주 | |
샴 군 | 380.7± 29.0 | 365.0 ± 57.7 | 430.0 ± 57.7 | 460.0 ± 46.2 |
BMP2 | 370.6 ± 24.8 | 368.3 ± 74.7 | 382.5 ± 141.5 | 470.0 ± 40.9 |
BMP9 | 366.8 ± 34.2 | 442.0 ± 79.8 | 505.0 ± 77.6 | 508.0 ± 60.6 |
2 주 | 4 주 | 6 주 | 8 주 | |
샴 군 | 1.30 ± 0.11 | 1.29 ± 0.04 | 1.25 ± 0.21 | 1.10 ± 0.0 |
BMP2 | 1.24 ± 0.14 | 1.25 ± 0.07 | 1.08 ± 0.07* | 1.04 ± 0.04 |
BMP9 | 1.19 ± 0.12 | 1.23 ± 0.10 | 1.06 ± 0.03* | 1.15 ± 0.07 |
2 주 | 4 주 | 6 주 | 8 주 | |
샴 군 | 3.98 ± 1.52 | 6.17 ± 1.27 | 6.33 ± 1.27 | 6.3 ± 1.31 |
BMP2 | 6.14 ± 1.51 | 7.51 ± 1.29 | 9.00 ± 1.69* | 7.17 ± 0.50* |
BMP9 | 6.79 ± 1.34* | 9.53 ± 4.47* | 9.47 ± 1.22* | 10.26 ± 2.27* |
Claims (19)
- 하기를 포함하는 신경재생 방법:a) 프로모터에 효과적으로 연결된 단백질의 형질전환 성장 인자 수퍼패밀리의 구성원을 암호화하는 DNA 서열을 포함하는 재조합 바이러스 또는 플라스미드 벡터를 제작하는 단계;b) 배양된 세포의 개체군을 재조합 벡터로 in vitro 형질전환하여, 배양된 세포의 개체군을 수득하는 단계; 및c) 손상된 신경 근처의 영역에서 DNA 서열의 발현이 신경의 재생을 야기하도록, 손상된 신경 근처 영역에 형질전환된 세포를 이식하는 단계.
- 제 1항에 있어서, 형질전환 성장 인자는 BMP인 것을 특징으로 하는 방법.
- 제 2항에 있어서, BMP가 BMP-2 및 BMP-9인 것을 특징으로 하는 방법.
- 제 1항에 있어서, 세포는 결합 조직 세포인 것을 특징으로 하는 방법.
- 제 4항에 있어서, 세포는 섬유아세포인 것을 특징으로 하는 방법.
- 제 1항에 있어서, 세포는 신경 세포인 것을 특징으로 하는 방법.
- 제 1항에 있어서, 신경은 말초신경인 것을 특징으로 하는 방법.
- 제 1항에 있어서, 벡터는 바이러스 벡터인 것을 특징으로 하는 방법.
- 제 8항에 있어서, 벡터는 레트로바이러스, 아데노-부속 바이러스 벡터, 아데노바이러스 벡터 또는 포진바이러스 벡터인 것을 특징으로 하는 방법.
- 제 1항에 있어서, 상기의 세포의 개체군은 이식 전에 저장되는 것을 특징으로 하는 방법.
- 제 4항에 있어서, 상기의 형질전환된 세포의 개체군은 이식 전에 액화 질소 하에 10% DMSO에 보관되는 것을 특징으로 하는 방법.
- 하기를 포함하는 신경 재생 방법:a) 수포 재생 단백질을 암호화하는 DNA 서열을 포함하는 재조합 바이러스 또는 플라스미드 벡터를 제작하는 단계;b) 배양된 세포의 개체군을 재조합 벡터로 in vitro 형질전환 하여, 배양된 세포의 개체군을 수득하는 단계; 및c) 손상된 신경 근처의 영역에서 DNA 서열의 발현이 신경의 재생을 야기하도록, 손상된 신경 근처 영역에 형질전환된 세포를 이식하는 단계.
- 제 12항에 있어서, 세포는 결합 조직 세포인 것을 특징으로 하는 방법.
- 제 13항에 있어서, 세포는 섬유아세포인 것을 특징으로 하는 방법.
- 제 12항에 있어서, 세포는 신경 세포인 것을 특징으로 하는 방법.
- 제 12항에 있어서, 세포는 신경교 세포인 것을 특징으로 하는 방법.
- 제 12항에 있어서, 세포는 슈반 세포인 것을 특징으로 하는 방법.
- 제 12항에 있어서, 단백질은 뉴레귤린-1(neuregulin-1)인 것을 특징으로 하는 방법.
- 제 12항에 있어서, 신경은 말초신경인 것을 특징으로 하는 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58262704P | 2004-06-23 | 2004-06-23 | |
US60/582,627 | 2004-06-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070039554A true KR20070039554A (ko) | 2007-04-12 |
KR100917403B1 KR100917403B1 (ko) | 2009-09-14 |
Family
ID=35782307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077001652A KR100917403B1 (ko) | 2004-06-23 | 2005-06-23 | 신경 재생 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20060014288A1 (ko) |
EP (1) | EP1784486B1 (ko) |
JP (1) | JP4576426B2 (ko) |
KR (1) | KR100917403B1 (ko) |
CN (1) | CN101031645B (ko) |
AT (1) | ATE527349T1 (ko) |
AU (2) | AU2005258101B2 (ko) |
CA (2) | CA2735272A1 (ko) |
DK (1) | DK1784486T3 (ko) |
ES (1) | ES2376332T3 (ko) |
WO (1) | WO2006002202A2 (ko) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Jx日鉱日石エネルギー株式会社 | 潤滑油組成物 |
ES2479942T3 (es) | 2003-04-18 | 2014-07-25 | Biogen Idec Ma Inc. | Neublastina glucosilada conjugada con polímero |
AU2005277227B2 (en) | 2004-08-19 | 2011-10-06 | Biogen Ma Inc. | Refolding transforming growth factor beta family proteins |
RS51453B (en) * | 2004-08-19 | 2011-04-30 | Biogen Idec Ma Inc. | NEUBLASTIN |
DK1904113T3 (en) | 2005-06-23 | 2016-03-21 | Tissuegene Inc | NEURO PROTECTIVE EFFECTIVE CONNECTION |
TWI501774B (zh) * | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
WO2007103182A2 (en) * | 2006-03-01 | 2007-09-13 | Biogen Idec Ma Inc. | Compostions and methods for administering gdnf ligand family proteins |
JP5583005B2 (ja) | 2007-05-01 | 2014-09-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管新生を増大させるための組成物および方法 |
EP2205634A2 (en) * | 2007-08-08 | 2010-07-14 | Biogen Idec MA, Inc. | Anti-neublastin antibodies and uses thereof |
US8438020B2 (en) * | 2007-10-12 | 2013-05-07 | Panasonic Corporation | Vector quantization apparatus, vector dequantization apparatus, and the methods |
JPWO2009110215A1 (ja) * | 2008-03-03 | 2011-07-14 | 独立行政法人科学技術振興機構 | 繊毛細胞の分化誘導方法 |
US20150159135A1 (en) * | 2012-06-15 | 2015-06-11 | Baylor College Of Medicine | Perineurium Derived Adult Stem Cells and Methods of Use |
US10595754B2 (en) | 2014-03-13 | 2020-03-24 | Sano Intelligence, Inc. | System for monitoring body chemistry |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210026A (en) * | 1990-08-20 | 1993-05-11 | American Cyanamid Company | Human mk gene and method of expression |
US6723698B2 (en) * | 1991-03-11 | 2004-04-20 | Curis, Inc. | Methods and compositions for the treatment of motor neuron injury and neuropathy |
AU681594B2 (en) * | 1992-07-31 | 1997-09-04 | Stryker Corporation | Morphogen-induced nerve regeneration and repair |
CA2169191C (en) * | 1993-08-26 | 2008-01-15 | Elizabeth A. Wang | Neural regeneration using human bone morphogenetic proteins |
US7011827B2 (en) * | 1993-11-09 | 2006-03-14 | Trustees Of The University Of Pennsylvania | Compositions and methods for producing and using homogenous neuronal cell transplants |
EP1095159A4 (en) * | 1998-07-15 | 2003-01-02 | Human Genome Sciences Inc | Bone Morphogenetic Protein |
US6743613B2 (en) * | 1999-04-23 | 2004-06-01 | Human Genome Sciences, Inc. | Lysyl-oxidase HOHEC84 polynucleotides |
WO2001017547A2 (en) * | 1999-09-08 | 2001-03-15 | Genetics Institute, Inc. | Bmp-9 compositions and methods for inducing differentiation of cholinergic neurons |
US6696410B1 (en) * | 1999-09-27 | 2004-02-24 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors |
CN1319423A (zh) * | 2001-02-19 | 2001-10-31 | 南通医学院 | 神经再生素及其生产方法和用途 |
IL147412A0 (en) * | 2001-12-31 | 2002-08-14 | Yeda Res & Dev | The use of il6r/il6 chimera in nerve cell regeneration |
US20050013870A1 (en) * | 2003-07-17 | 2005-01-20 | Toby Freyman | Decellularized extracellular matrix of conditioned body tissues and uses thereof |
EP1709161B1 (en) * | 2004-01-19 | 2008-10-01 | Nsgene A/S | Human therapeutic cells secreting nerve growth factor |
-
2005
- 2005-06-23 US US11/160,446 patent/US20060014288A1/en not_active Abandoned
- 2005-06-23 WO PCT/US2005/021993 patent/WO2006002202A2/en active Application Filing
- 2005-06-23 EP EP05762470A patent/EP1784486B1/en active Active
- 2005-06-23 CN CN2005800265162A patent/CN101031645B/zh active Active
- 2005-06-23 CA CA2735272A patent/CA2735272A1/en not_active Abandoned
- 2005-06-23 AT AT05762470T patent/ATE527349T1/de not_active IP Right Cessation
- 2005-06-23 CA CA2571318A patent/CA2571318C/en active Active
- 2005-06-23 AU AU2005258101A patent/AU2005258101B2/en active Active
- 2005-06-23 DK DK05762470.2T patent/DK1784486T3/da active
- 2005-06-23 KR KR1020077001652A patent/KR100917403B1/ko active IP Right Grant
- 2005-06-23 JP JP2007518217A patent/JP4576426B2/ja active Active
- 2005-06-23 ES ES05762470T patent/ES2376332T3/es active Active
-
2009
- 2009-05-07 AU AU2009201827A patent/AU2009201827B2/en active Active
-
2021
- 2021-10-13 US US17/500,832 patent/US20220241433A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1784486B1 (en) | 2011-10-05 |
EP1784486A4 (en) | 2007-10-17 |
KR100917403B1 (ko) | 2009-09-14 |
AU2005258101B2 (en) | 2009-08-27 |
CA2571318C (en) | 2011-06-07 |
EP1784486A2 (en) | 2007-05-16 |
CA2571318A1 (en) | 2006-01-05 |
CN101031645A (zh) | 2007-09-05 |
CN101031645B (zh) | 2011-06-08 |
CA2735272A1 (en) | 2006-01-05 |
US20220241433A1 (en) | 2022-08-04 |
ATE527349T1 (de) | 2011-10-15 |
WO2006002202A3 (en) | 2006-10-12 |
AU2009201827A1 (en) | 2009-05-28 |
DK1784486T3 (da) | 2012-01-16 |
US20060014288A1 (en) | 2006-01-19 |
AU2005258101A1 (en) | 2006-01-05 |
JP2008504269A (ja) | 2008-02-14 |
JP4576426B2 (ja) | 2010-11-10 |
WO2006002202A2 (en) | 2006-01-05 |
ES2376332T3 (es) | 2012-03-13 |
AU2009201827B2 (en) | 2013-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100917403B1 (ko) | 신경 재생 | |
Harvey et al. | Neurotrophic factors and the regeneration of adult retinal ganglion cell axons | |
Ke et al. | Netrin-1 overexpression in bone marrow mesenchymal stem cells promotes functional recovery in a rat model of peripheral nerve injury | |
Chamberlain et al. | A review of the cellular and molecular effects of extracorporeal shockwave therapy | |
Haastert et al. | Gene therapy in peripheral nerve reconstruction approaches | |
Li | Deer antler renewal gives insights into mammalian epimorphic regeneration | |
JP5849109B2 (ja) | 神経保護効果のある化合物 | |
RU2538621C2 (ru) | Способ стимулирования восстановления иннервации тканей после травм и ишемии с помощью векторной конструкции | |
Wei | Type XII collagen, fibroblast growth factor-1, and fibroblast growth factor-4 in newt limb and tail regeneration | |
Hercher | Design and in vitro Characterization of Therapeutic Expression Systems for ex vivo Neuroprotective Gene Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E90F | Notification of reason for final refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
E801 | Decision on dismissal of amendment | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
E801 | Decision on dismissal of amendment | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120822 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20130910 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151012 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160908 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170906 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180829 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190904 Year of fee payment: 11 |